NO941629L - Peptides that inhibit 1L-1 - Google Patents

Peptides that inhibit 1L-1

Info

Publication number
NO941629L
NO941629L NO941629A NO941629A NO941629L NO 941629 L NO941629 L NO 941629L NO 941629 A NO941629 A NO 941629A NO 941629 A NO941629 A NO 941629A NO 941629 L NO941629 L NO 941629L
Authority
NO
Norway
Prior art keywords
substituted
ring
amino acid
peptides
inhibit
Prior art date
Application number
NO941629A
Other languages
Norwegian (no)
Other versions
NO941629D0 (en
Inventor
Richard Heng
Trevor Glyn Payne
Laszlo Revesz
Beat Weidmann
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NO941629D0 publication Critical patent/NO941629D0/en
Publication of NO941629L publication Critical patent/NO941629L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Di-, tri og tetrapeptider hvor den siste a-aminosyren er basert på asparaginsyre og bundet til en rest A5 som er H, CF3, -Z1-Z2-Y2 hvor hver av Z^ og Z2 uavhenging er en direkte binding eller en d-aminosyrerest og Y2 er NH2, C^alkylamino, di-CCi^alkyDamino eller et heterosyklisk radikal bundet ved et nitrogen til Z2, -CHj-Xj-Yj hvor Xt er O eller S og Y3 er heteroaryl, -CH2-Y3, substituert fenyl, ringsubstituert fen- oksymetylen eller fenyltiometylen, ringsubstituert pyridyl- oksymetylen, eller et radikal -CHj-Xj-CO-Y, hvor Xj er O eller S og Y4 er trialkylmetyl eller substistuert fenyl eller pyri- dyl, i fri form eller i saltform, og som har farmakologisk aktivitet, f.eks. inhibering av IL-lp-frigivelse.Di-, tri- and tetrapeptides where the last α-amino acid is based on aspartic acid and bound to a residue A5 which is H, CF3, -Z1-Z2-Y2 where each of Z amino acid residue and Y 2 are NH 2, C 1-6 alkylamino, di-CC 1-4 alkydamino or a heterocyclic radical attached by a nitrogen to Z 2, -CH 2 -X 2 -Y 2 , ring-substituted phenoxymethylene or phenylthiomethylene, ring-substituted pyridyloxymethylene, or a radical -CH₂-X₂-CO-Y, wherein X X is O or S and Y and having pharmacological activity, e.g. inhibition of IL-1β release.

NO941629A 1991-11-04 1994-05-03 Peptides that inhibit 1L-1 NO941629L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919123326A GB9123326D0 (en) 1991-11-04 1991-11-04 Improvements in or relating to organic compounds
PCT/EP1992/002472 WO1993009135A1 (en) 1991-11-04 1992-10-29 Peptides inhibiting il-1 beta release

Publications (2)

Publication Number Publication Date
NO941629D0 NO941629D0 (en) 1994-05-03
NO941629L true NO941629L (en) 1994-07-04

Family

ID=10703998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941629A NO941629L (en) 1991-11-04 1994-05-03 Peptides that inhibit 1L-1

Country Status (16)

Country Link
EP (1) EP0611375A1 (en)
JP (1) JPH07500828A (en)
AU (1) AU2885292A (en)
CA (1) CA2116653A1 (en)
CZ (1) CZ106794A3 (en)
FI (1) FI942061A (en)
GB (1) GB9123326D0 (en)
HU (1) HUT68200A (en)
IL (1) IL103612A0 (en)
MX (1) MX9206306A (en)
NO (1) NO941629L (en)
NZ (1) NZ244985A (en)
PT (1) PT101027A (en)
SK (1) SK51194A3 (en)
WO (1) WO1993009135A1 (en)
ZA (1) ZA928511B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DE69226820T2 (en) * 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidyl derivatives as inhibitors of interleukin-1B converting enzymes
AU3666893A (en) * 1992-02-21 1993-09-13 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
EP0618223A3 (en) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibiting interleukin 1-bêta release useful as antiinflammatory agents.
TW494094B (en) * 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5985838A (en) * 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (en) * 1993-06-03 1995-04-04 Sterling Winthrop Inc Interleukin-1 beta transfer enzyme inhibitor
ATE170868T1 (en) * 1993-06-04 1998-09-15 Vertex Pharma PEPTIDE PHOSPHINYLOXYMETHYL KETONES AS INHIBITORS OF INTERLEUKIN-1 BETA-CONVERTING ENZYMES
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
WO1995005192A1 (en) * 1993-08-13 1995-02-23 Merck & Co., Inc. SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US6162828A (en) * 1995-03-31 2000-12-19 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) * 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
EP0761680A3 (en) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
WO1997024339A1 (en) * 1995-12-27 1997-07-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6306613B1 (en) 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
AU6339198A (en) * 1997-02-26 1998-09-18 Ciblex Corporation Inhibitors of leaderless protein export
DE69925581T2 (en) 1998-03-09 2006-04-27 Vertex Pharmaceuticals Inc., Cambridge 1,2-DIAZEPANDERIVATE AS INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME
KR100928878B1 (en) 1998-03-19 2009-11-30 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of caspases
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
BR0009610A (en) * 1999-04-09 2002-02-13 Cytovia Inc Caspase inhibitors and their use
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
PE20011350A1 (en) 2000-05-19 2002-01-15 Vertex Pharma PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE)
CA2418720A1 (en) * 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
EP1483241A4 (en) 2002-03-08 2006-12-13 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
EP2399916B1 (en) 2004-03-12 2014-12-10 Vertex Pharmaceuticals Incorporated Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors
EP1778221A2 (en) 2004-05-27 2007-05-02 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
CN101979403A (en) * 2010-09-13 2011-02-23 沈陵陵 Novel broad caspase inhibitor and preparation method and application thereof
EP2635906A4 (en) 2010-11-05 2014-04-02 Univ Brandeis Ice inhibiting compounds and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
CN108473499B (en) 2015-11-13 2021-07-23 诺华股份有限公司 Novel pyrazolopyrimidine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (en) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE

Also Published As

Publication number Publication date
NO941629D0 (en) 1994-05-03
HUT68200A (en) 1995-05-29
NZ244985A (en) 1995-06-27
FI942061A0 (en) 1994-05-04
PT101027A (en) 1994-02-28
ZA928511B (en) 1994-05-04
MX9206306A (en) 1993-05-01
FI942061A (en) 1994-05-04
WO1993009135A1 (en) 1993-05-13
CA2116653A1 (en) 1993-05-13
GB9123326D0 (en) 1991-12-18
AU2885292A (en) 1993-06-07
IL103612A0 (en) 1993-04-04
EP0611375A1 (en) 1994-08-24
HU9401303D0 (en) 1994-08-29
JPH07500828A (en) 1995-01-26
CZ106794A3 (en) 1994-12-15
SK51194A3 (en) 1995-02-08

Similar Documents

Publication Publication Date Title
NO941629L (en) Peptides that inhibit 1L-1
WO2002080858A3 (en) Use of kpv tripeptide for dermatological disorders
DK162246C (en) USE OF N- (4-PHENOXY-2,6-DIISOPROPYLPHENYL) -N'-TERT-BUTYL-THIOUR INGREDIENTS TO COMBAT WHITE FLUES
IL148553A0 (en) Backbone cyclized peptide analogs comprising more than one cyclization
NO974147L (en) Heterocycle carbonylamino acid hydroxyethylaminosulfonamide retroviral protease
DE3875538D1 (en) AMINOLUCIFERINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE.
DK1649023T3 (en) Polypeptide with enhanced cytosine deaminase activity
CA2245267A1 (en) Crystal form of n-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
DE69012901D1 (en) Hemoregulating peptides.
NO932377D0 (en) ANTIVIRAL RELATIONS
ES548052A0 (en) PROCEDURE FOR PREPARING PEPTIDES
DE69330268D1 (en) HEMOREGULATING PEPTIDES
ES2051647A1 (en) Procedure for preparing salmon calcitonin.
DK0579785T3 (en) Substituted benzhydrylamines as tethering molecules for solid phase peptide synthesis
DK0971886T3 (en) Process for the preparation of N-alkyl-N'-nitroguanidines
DK0970052T3 (en) Process for preparing 5-aminomethyl-2-chloropyridines
DE50203418D1 (en) PROCESS FOR THE PREPARATION OF PYRROLIDONES
ATE265221T1 (en) MODIFIED, SHORTENED REGULATORS OF THE COMPLEMENT SYSTEM
ATE178909T1 (en) INHIBITOR PEPTIDE SPECIFIC TO CATHEPSIN-L
EP0248231A3 (en) Pharmacologically active peptides
ATE46173T1 (en) PHARMACOLOGICALLY ACTIVE PEPTIDES.
ATE154027T1 (en) GLYCOSYLAMIDES FROM 2-AMINOACYLAMINO-2-DESOXY SUGAR
DK0722460T3 (en) Peptide derivatives that are therapeutically active in the blood coagulation cascade, methods of preparing them, and pharmaceuticals
DK1390055T3 (en) Tripeptide derivatives for the treatment of post-lesion disorders of the nervous system
DK0570244T3 (en) Process for the preparation of peptides having a C-terminal prolinamide